TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02036866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 8 hours per day for 1 week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 8 hours per day for 1 week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy Exercises
Description: Patients will be given detailed verbal and hands-on instruction in a home exercise program. This program will consist of 6 exercises modeled from established protocols focuses on improving lower extremity strength. Patients will be instructed to do the exercises daily and to progress the exercises over the week for a maximum of 30 repetitions per day for 1 week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy Exercises
Description: Patients will be given detailed verbal and hands-on instruction in a home exercise program. This program will consist of 6 exercises modeled from established protocols focuses on improving lower extremity strength. Patients will be instructed to do the exercises daily and to progress the exercises over the week for a maximum of 30 repetitions per day for 1 week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: Patients will be instructed to maintain their usual activity level.
Study: NCT03483545

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Follitropin delta and HP-hMG
Description: Follitropin delta dose will be determined by AMG and weight in Kg. Highly purified human menopausal gonadotrophin will be determined by follitropin delta dose and body weight in Kg
Study: NCT03094845

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: 15 injections over 7 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hdmASIT+TM
Description: 15 injections over 7 weeks
Study: NCT00624494

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional monitoring
Description: In the CM group, therapy was guided by central venous pressure, mean arterial pressure (MAP) and heart rate (HR)
Study: NCT04480632

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: ABO compatible convalescent plasma obtained from from recovered COVID-19 patients
Study: NCT01012778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Climb Up ADHD and Dyslexia Program
Description: Using a peer mediated multimodal intervention program for ADHD and Dyslexia use Yoga, Meditation, Play therapy administered by (trained) high school volunteers
Study: NCT03888729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbubir/velpatasvir
Description: SOF/VEL (400 mg/100 mg) FDC once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbubir/velpatasvir/voxilaprevir
Description: SOF/VEL/VOX (400 mg/100 mg/100 mg) FDC once daily
Study: NCT02240264

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Krill oil capsules
Description: 1 year supplementation with Krill oil provided by Aker BioMarine Antarctic AS equalling almost the daily recommended amount of 450 mg of EPA/DHA intake per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing a fatty acid mixture that reflects the fatty acid composition of the average European diet.
Study: NCT00230542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given intravenously following pemetrexed over 30-45 minutes once every three weeks for 6 cycles (18 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given intravenously over 30 minutes once every three weeks for 6 cycles (18 weeks)
Study: NCT01114828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061
Description: Once-daily oral administration of OPC-41061 at 3.75 mg after breakfast for 7 days
Study: NCT00624494

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Advanced monitoring
Description: In the AM group by the intrathoracic blood volume index, MAP, HR, central venous oxygen saturation (ScvO2) and cardiac index (CI). The measurements were performed before and during surgery, and at 2, 4 and 6 hrs post-operatively.
Study: NCT01433679

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zamzee Intervention
Description: The Zamzee intervention is designed to motivate middle school-aged children to increase their rates of moderate to vigorous physical activity (MVPA) by providing rewards based on amount and duration of physical activity. Rewards include gift cards to retail stores, donations to charity, small tangible goods, and customization of their cartoon-like avatars on the website.
Study: NCT01114828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061
Description: Once-daily oral administration of OPC-41061 at 7.5 mg after breakfast for 7 days
Study: NCT02589106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anisotropic Textile Braces
Description: The period of the wear trial is 12-18 months in time for each subject. Wear instructions (23 hrs per day) and wash instructions will be provided to the subjects before the wear trial. Evaluation tests based on health in consideration of the use of the anisotropic textile brace (heart and pulmonary function testing and sensory level measurements) will be carried out at the beginning of the wear trial. Clinical, radiography, self-report and follow-up after completion of the study
Study: NCT04560153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: karate kata
Description: sessions of karate kata every week during 4 months
Study: NCT02053181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadazolid
Description: Cadazolid was provided as dry powder for oral suspension (Amber glass bottles of 60 mL). The powder was reconstituted with tap water by a pharmacist immediately prior to dispensing to subjects.
Study: NCT00376909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Study: NCT00917839

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lamotrigine
Description: 100 mg, once daily, 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamotrigine
Description: 100 mg, once daily, 12 months
Study: NCT03761810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S6G5T-3
Description: Once a day topical cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S6G5T-8
Description: Once a day topical cream
Study: NCT02267538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine hydrochloride for injection
Description: Before anesthesia, dexmedetomidine hydrochloride for injection (200 ug/2 ml) will be diluted with normal saline to 50 ml (final dexmedetomidine concentration 4 ug/ml).~Before the induction of anesthesia, a loading dose will be administered by intravenous infusion at a rate of \[0.9\*kg\] ml/h for 10 minutes (i.e., dexmedetomidine 0.6 μg/kg in 10 minutes), followed by continuous infusion at a rate of \[0.1\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.4 μg /kg/h) until the end of surgery.~At the end of surgery, the infusion rate will be decreased to \[0.025\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.1 ug/kg/h) and continued until the end of mechanical ventilation after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride for injection
Description: Before anesthesia, 0.9% sodium chloride for injection 50 ml will be prepared.~Before the induction of anesthesia, a loading dose will be administered by intravenous infusion at a rate of \[0.9\*kg\] ml/h for 10 minutes, followed by continuous infusion at a rate of \[0.1\*kg\] ml/h until the end of surgery.~At the end of surgery, the infusion rate will be decreased to \[0.025\*kg\] ml/h and continued until the end of mechanical ventilation after surgery.
Study: NCT03892239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RunIn3 Prevention Program
Description: The intervention will be delivered online. Every two weeks we will send a link to participants that will direct them to an online questionnaire. The online questionnaire will collect information on complaints and symptoms related to running, and the volume, intensity and frequency of running practice within the 2-week period. If the participant reports any symptom and if she/he accepts a suggestion regarding running training, an algorithm embedded in the online system will automatically suggest a training volume for the next two weeks based on the distance and/or duration reported by the participant.~Through a website we will make available informative texts, videos and infographics in order to increase the participant's knowledge regarding topics such as: musculoskeletal symptoms; foot strike patterns; training workload; running shoes; warming-up/cooling-down, stretching; and concomitant strength training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feedback Based Surveillance
Description: The intervention will be delivered online. Every two weeks we will send a link to participants that will direct them to an online questionnaire. The online questionnaire will collect information on complaints and symptoms related to running, and the volume, intensity and frequency of running practice within the 2-week period. If the participant reports any symptom and if she/he accepts a suggestion regarding running training, an algorithm embedded in the online system will automatically suggest a training volume for the next two weeks based on the distance and/or duration reported by the participant.
Study: NCT03229733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinect
Description: Receive Kinect games training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional occupational therapy
Description: Patients will receive individually tailored conventional training consisting of the similar movement and dose by using the traditional equipment, such as climbing bar.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional occupational therapy
Description: Patients will receive individually tailored conventional training consisting of the similar movement and dose by using the traditional equipment, such as climbing bar.
Study: NCT04681209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DRT Condition
Description: Children were asked to provide five descriptors of two children who each engaged in defending behaviors. Two weeks later they were told the top seven descriptors given by the hundreds of children participating in the project. This was followed by a brief discussion of how one could best help another kid who was getting bullied. Children then made posters to share with younger grades as to what friendship heroes are like, using the descriptor words shared with them, and how to be a friendship hero (i.e., how to help someone who is being bullied). Posters were hung for two-to-four months after the intervention activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Empathy Condition
Description: Children in the empathy-based condition were asked to provide five descriptors of how two children who were bullied would fee. Two weeks later they were told the top seven descriptors given by the hundreds of children participating in the project. This was followed by a brief discussion of how one could best help another kid who was getting bullied. Children then made posters to share with younger grades as to what being bullied feels like, using the descriptor words shared with them, and how to be a friendship hero (i.e., how to help someone who is being bullied). Posters were hung for two-to-four months after the intervention activity.
Study: NCT00376909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: study of socioeconomic and demographic variables
Study: NCT02203513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2606368
Description: 105 mg/m\^2 intravenous (IV) once every 14 days of a 28 day cycle
Study: NCT01148108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canfosfamide HCl for injection
Description: 30 min. intravenous infusion of canfosfamide HCl (1000 mg/m2) every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canfosfamide HCl for injection
Description: 30 min. intravenous infusion of canfosfamide HCl (1000 mg/m2) every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canfosfamide HCl for injection
Description: 30 min. intravenous infusion of canfosfamide HCl (1000 mg/m2) every 2 weeks
Study: NCT02784665

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 577-MPL
Description: All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm affected area in micropulse model.The power titration was started at 700 milliwatt(mW) and then gradually increased until a just visible burn was seen. When this threshold was reached, the power was reduced by 50%, using a 100-μm spot diameter and a 200-ms duration with 5 % duty cycle LaserSystem) in 577-MPL arm. The individual power for the patient was titrated at a normal area of near the

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 577-TL
Description: All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm LaserSystem) in 577-TL arm.~100 microns light spot size, 0.05 seconds duration, 80 \~ 200 milliwatts of power
Study: NCT03422965

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Optical Coherence Tomography Angiography
Description: Optical Coherence Tomography Angiography images capture.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Optical Coherence Tomography Angiography
Description: Optical Coherence Tomography Angiography images capture.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Blood test
Description: Blood test, systemic markers

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood test
Description: Blood test, systemic markers
Study: NCT02599155

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Crystalloid
Description: normal saline administration for volume expansion in hypovolemic status

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloid
Description: HES 130/0.4 administration for volume expansion in hypovolemic status
Study: NCT03422965

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Urine test
Description: Urine test, systemic markers

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Urine test
Description: Urine test, systemic markers
Study: NCT03063905

Intervention type: DRUG
Intervention: Buprenorphine
Description: Patients taking buprenorphine to wean off an opiate addiction

Intervention type: DRUG
Intervention: Buprenorphine
Description: Patients taking buprenorphine to wean off an opiate addiction
Study: NCT04125277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FES-PET scan, and possibly one additional visit for an FDG-PET
Description: One visit to either the UMCG or Amsterdam UMC-location VUMC is required for the FES-PET scan, and possibly one additional visit for an FDG-PET. A FES- or FDG-PET scan plus low dose CT will each induce an extra radiation burden of about 6.1 mSv (210 MBq injected for an average patient of 70 kilogram body weight).
Study: NCT03406897

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Oral Administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Oral Administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acid
Description: Oral Administration
Study: NCT02476006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALIROCUMAB SAR236553 (REGN727)
Description: Pharmaceutical form:solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo (for injection training only)
Description: Pharmaceutical form:solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe
Description: Pharmaceutical form:capsule Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT03956524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EuTCV
Description: Single 0.5 mL dose of TCV of EuBiologics co., Ltd.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Typbar-TCV™
Description: Single 0.5 mL dose of TCV of Bharat Biotech

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Typhim Vi®
Description: Single 0.5 mL dose of Vi capsular polysaccharide vaccine of Sanofi Pasteur
Study: NCT01010308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadolol
Description: Nadolol will be administered orally at home starting at 0.5 mg/kg/day divided into 2 doses. Weekly, if BP and heart rate are acceptable, the dose will be increased by 0.5 mg/kg/day up to 2 mg/kg/day.
Study: NCT00239707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIP
Description: One-time 20 ng/kg/min infusion over 3 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modified GIP
Description: One-time infusion over 3 hours; dose to maintain desired biological effect of below 140 mg/dl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: one-time infusion over 3 hours
Study: NCT01769040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 550 mg two times daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01341600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole/Clopidogrel
Description: After a washout of at least 1 week, participants will have the option to participate in a final intervention in which they will be given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole/Clopidogrel
Description: After a washout of at least 1 week, participants will have the option to participate in a final intervention in which they will be given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole/Clopidogrel
Description: After a washout of at least 1 week, participants will have the option to participate in a final intervention in which they will be given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
Study: NCT02629692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vodobatinib (K0706) capsules
Description: Part A: Vodobatinib (K0706) capsules in single ascending doses.~Part B: Oral Vodobatinib (K0706) capsules in multiple ascending doses, once daily.~Part C: Oral Vodobatinib (K0706) capsules at recommended phase 2 dose of 174 mg, once daily.
Study: NCT00675220

Intervention type: DRUG
Intervention: insulin aspart
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT00858442

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: With PRP
Description: Release of burn contractures and skin graft on the affected limb, a rigorous haemostasis. The surgeon must distribute the activated PRP evenly, forming a very fine clot over it. Immediately the split skin graft must be applied, duly fenestrated. The grafted zone will be measured in it's longest width and length, taking a standardized photograph. On the 5th day the nurse will evaluate the graft's conditions. The evaluation will be done following a previously established follow-up protocol. Measurements of width \& length of graft and standardized photo taken at the initiation of the compressive system. Measurement of graft's width \& length and standardized photo at the end of the compressive system according protocol. Statistical analysis.
Study: NCT02710890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Pharmaceutical form: solution for infusion~Concentration: 10 mg/ml~Route of Administration: intravenous
Study: NCT04526483

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy with Intelligent Navigation 4K UHD 3D Endoscopic Imaging System
Description: Laparoscopic gastrectomy with Intelligent Navigation 4K UHD 3D Endoscopic Imaging System
Study: NCT04800003

Intervention type: DIAGNOSTIC_TEST
Intervention: Gonial angle and submandibular fossa depth measurements from CBCT images
Description: CBCT images were obtained from dry human mandibles
Study: NCT03669120

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive advice to quit smoking and materials to promote smoking cessation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive advice to quit smoking and materials to promote smoking cessation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive individualized text based messages